Myelodysplastic syndrome

Myelodysplastic syndromes (MDS) represent a group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis. This means that the stem cells residing in the bone marrow, which are responsible for producing all mature blood cell lineages, are unable to differentiate properly. Instead of maturing into functional red blood cells, white blood cells, and platelets, these cells often undergo apoptosis (programmed cell death) within the marrow, or they mature into dysplastic, non-functional forms.

This leads to a paradoxical situation: the bone marrow may appear hypercellular, yet there is a profound deficiency in mature peripheral blood cells, a condition known as cytopenia. The specific lineage affected (erythroid, myeloid, or megakaryocytic) dictates the primary clinical manifestations, such as anemia, neutropenia, or thrombocytopenia.

The precise etiology of MDS is often unknown (idiopathic), but several risk factors have been identified. Secondary MDS can arise following genotoxic exposures, most notably prior chemotherapy and radiation therapy for other malignancies. The cumulative damage to DNA within hematopoietic stem cells can disrupt crucial signaling pathways and genetic regulators of differentiation.

Environmental exposures, including certain industrial chemicals (like benzene), pesticides, and heavy metals (mercury, lead), are also implicated. Genetic factors play a role, with increasing incidence observed in older individuals, suggesting an accumulation of somatic mutations over time. Specific chromosomal abnormalities, such as deletions on chromosomes 5, 7, or 20, or trisomy 8, are frequently observed in MDS cells and are critical for classification and prognosis.

Patients with MDS often present with symptoms related to their cytopenias. Anemia can manifest as fatigue, pallor, and dyspnea on exertion. Neutropenia increases susceptibility to recurrent or severe infections, while thrombocytopenia can lead to spontaneous bruising, petechiae, or prolonged bleeding.

Diagnosis relies on a combination of peripheral blood counts and a bone marrow examination. The peripheral blood smear may reveal characteristic dysplastic changes in blood cells. A bone marrow biopsy and aspirate are essential for assessing cellularity, identifying dysplastic morphology across all cell lineages, quantifying the percentage of blasts (immature myeloid cells), and performing cytogenetic and molecular analyses.

The International Prognostic Scoring System (IPSS) and its revised versions are used to stratify patients based on blast percentage, cytogenetic abnormalities, and cytopenias, guiding treatment decisions and predicting outcomes.

Treatment for MDS is tailored to the patient's age, overall health, MDS subtype, and risk stratification. Supportive care is foundational, including red blood cell transfusions for anemia, growth factors (like erythropoiesis-stimulating agents) to boost red blood cell production, and antibiotics or granulocyte colony-stimulating factor (G-CSF) to manage neutropenia and infections. For patients with specific genetic mutations or certain risk profiles, targeted drug therapies such as hypomethylating agents (azacitidine, decitabine) or immunomodulatory drugs (lenalidomide) can improve blood counts and potentially delay progression.

Hematopoietic stem cell transplantation (HSCT) remains the only potentially curative option for MDS, typically reserved for younger, fitter patients with higher-risk disease. Ongoing research focuses on understanding the molecular drivers of MDS to develop novel targeted therapies and improve the efficacy and safety of HSCT.

Myelodysplastic syndromes are considered rare, with an incidence of approximately 7 per 100,000 people globally. The incidence rises sharply with age, with the median age at diagnosis being around 70 years. The prognosis for MDS is highly variable and depends on several factors, including the specific subtype of MDS, the percentage of blasts in the bone marrow and peripheral blood, the presence and type of chromosomal abnormalities, and the degree of cytopenias.

The median survival can range from less than a year for high-risk MDS to several years for lower-risk forms. A critical concern is the risk of transformation to acute myeloid leukemia (AML), which occurs in a significant proportion of patients and carries a poorer prognosis. MDS was first recognized in the early 20th century, with the term 'myelodysplastic syndrome' being established in 1976, reflecting a growing understanding of these complex bone marrow disorders.